AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 72 min read$ASST

8 Health Care Stocks Whale Activity In Today’s Session - Strive (NASDAQ:ASST), AirSculpt Technologies (NA

Benzinga reports unusual options activity in healthcare stocks. ASST sees bullish call options, while AIRS, PURR, GSK, HIMS, and MRNA show bearish activity. CYPH and UNH have bullish call sweeps. Details include strike prices, volumes, and expiration dates.

Original reporting
benzinga.com
Published Sep 7, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 7, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ASST
Bullish
medium confidence
Mentioned
$ASST · $AIRS · $PURR · $GSK · $HIMS · $CYPH
Relevance
5/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ASSTBullishMed
01

Why it matters

Large, atypical option trades can foreshadow price moves as large traders position ahead of news or earnings.

02

Market read

Unusual options activity across multiple health care stocks may signal near-term volatility and directional moves.

03

What to watch

Option activity may reflect hedging around upcoming earnings or regulatory events not disclosed yet.

Relevance 5/10Novelty 6/10Timing: today's session

Background

The article lists unusual options activity for eight healthcare-related stocks observed in today's trading session.

Company-level read

Ticker impact

$ASSTBullishMedium confidence
Context

Bullish call option trade on ASST with 461 contracts at $26 strike, $106K total trade price.

Expected impact

Potential short-term price rise if buying pressure continues.

Evidence & confidence

Unusual volume and high premium indicate strong interest from large traders.

$AIRSBearishMedium confidence
Context

Bearish call sweep on AIRS with 200 contracts at $1 strike, $38K total trade price.

Expected impact

Possible short-term decline or increased volatility.

Evidence & confidence

Sweep across multiple accounts suggests coordinated bearish positioning.

$PURRBearishMedium confidence
Context

Bearish call trade on PURR with 200 contracts at $15 strike, $42K total trade price.

Expected impact

Likely short-term downside pressure.

Evidence & confidence

Large trade size relative to open interest indicates strong bearish sentiment.

$GSKBearishMedium confidence
Context

Bearish put trade on GSK with 780 contracts at $45 strike, $280.8K total trade price.

Expected impact

Potential downward move or heightened volatility.

Evidence & confidence

Unusual put volume and premium point to bearish positioning by large players.

$HIMSBearishMedium confidence
Context

Bearish call trade on HIMS with 450 contracts at $32 strike, $117K total trade price.

Expected impact

Possible short-term price stagnation or decline.

Evidence & confidence

Large trade size and bearish sentiment reflect negative outlook.

$CYPHBullishMedium confidence
Context

Bullish call sweep on CYPH with 200 contracts at $1 strike, $31K total trade price.

Expected impact

Potential short-term rally.

Evidence & confidence

Sweep across multiple accounts shows strong buying interest.

$MRNABearishMedium confidence
Context

Bearish call sweep on MRNA with 25 contracts at $155 strike, $28.3K total trade price.

Expected impact

Possible short-term decline.

Evidence & confidence

Even small sweep at high strike indicates bearish positioning.

$UNHBullishMedium confidence
Context

Bullish call sweep on UNH with 50 contracts at $440 strike, $47.2K total trade price.

Expected impact

Potential short-term price increase.

Evidence & confidence

Large premium and sweep indicate strong bullish interest.

Market effects

Sector

Healthcare sector shows divergent option sentiment, indicating mixed short-term outlook.

Regional

U.S. market participants may adjust exposure to affected healthcare stocks.

Global

Limited to U.S.-listed healthcare companies; minimal global spillover.

Counterpoint

What could challenge this read

Bearish sweeps on several stocks may precede a sector pullback despite isolated bullish activity.

Key entities

  • stock
    ASST

    Health care company with bullish call activity.

  • stock
    AIRS

    Health care company with bearish call sweep.

  • stock
    PURR

    Health care company with bearish call activity.

  • stock
    GSK

    Pharmaceutical giant with heavy put buying.

  • stock
    HIMS

    Health care firm with bearish call trade.

Read at source← All news

Related articles

OCT 24
$MRNAHigh

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Moderna's melanoma therapy, intismeran, reduced recurrence risk by 42% in a Phase 3 trial. The combination therapy also improved distant metastasis-free survival. The company reported successful manufacturing and safety profiles. Moderna is exploring the therapy in other cancer types. According to the company, intismeran is designed to stimulate immune responses against tumor-specific mutations.

finance.yahoo.com2 min
OCT 24
$IBBMedAI 8/10

Biotech ETF Rises 23% as Drug Milestones Span Trials to Approval

The iShares Biotechnology ETF (IBB) rose 23.1% through Oct. 23, driven by drug milestones. Merck and Moderna reported positive Phase 3 trial data for intismeran autogene. Roche's Enspryng gained FDA approval for thyroid eye disease. Eli Lilly plans to submit a weight-loss drug for FDA review in early 2027. IBB's expense ratio is 0.44%, while SPDR S&P Biotech ETF (XBI) has a 0.35% expense ratio.

econotimes.com2 min
OCT 24
$MRNAHigh

Doctors cheer while investors bounce over cancer vaccine

Moderna and Merck's melanoma vaccine trial showed a 42% reduction in tumor recurrence and 38% in distant spread, impressing doctors. However, shares of both companies fell as investors questioned the vaccine's broader potential and commercial success. Analysts raised concerns about costs and competition. The full data will be presented at a medical conference.

bostonherald.com3 min
OCT 24
$MRKMed

Merck and Moderna Report 42% Relative Risk Reduction in Melanoma Trial

Merck and Moderna reported Phase 3 trial results showing their personalized mRNA therapy, combined with Keytruda, reduced melanoma recurrence or death risk by 42% compared to Keytruda alone. The study involved 1,137 patients, with 2-year recurrence-free survival at 82.2% for the combination vs. 70.0% for Keytruda. The therapy is still investigational, and the companies are engaging with regulators.

tokenpost.com2 min
OCT 24
$MRKHigh

Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma

A phase 3 trial showed intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in resected stage IIB to IV melanoma. The combination reduced the risk of recurrence or death by 42% (HR, 0.58; P < .001) and distant metastasis or death by 38% (HR, 0.62; P = .002). 24-month RFS rates were 82.2% vs 70.0%, and DMFS rates were 88.5% vs 80.2%.

onclive.com3 min